Sanjay Gandhi to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications Sanjay Gandhi has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
1.361
-
Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective. Clin Ther. 2008 Jul; 30(7):1345-57.
Score: 0.274
-
Ohsfeldt RL, Olsson AG, Jensen MM, Gandhi SK, Paulsson T. Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial. J Med Econ. 2012; 15(1):125-33.
Score: 0.086
-
Ohsfeldt RL, Gandhi SK, Smolen LJ, Jensen MM, Fox KM, Gold A, Hsia J. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. J Med Econ. 2010; 13(3):428-37.
Score: 0.076
-
Gandhi SK, Järbrink K, Fox KM, Brandrup-Wognsen G. Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice. Curr Med Res Opin. 2009 Dec; 25(12):2817-28.
Score: 0.076
-
Ohsfeldt RL, Gandhi SK, Fox KM. Medicare-eligible patients diagnosed with atherosclerosis: patterns in statin therapy and lipid monitoring. Curr Med Res Opin. 2009 Jun; 25(6):1403-11.
Score: 0.073
-
Davidson MH, Gandhi SK, Ohsfeldt RL, Fox KM. Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice. Am J Med. 2009 Jan; 122(1 Suppl):S51-9.
Score: 0.071
-
Ohsfeldt RL, Gandhi SK, Fox KM, McKenney JM. Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications. Value Health. 2008 Dec; 11(7):1061-9.
Score: 0.068
-
Harley CR, Gandhi SK, Heien H, McDonough K, Nelson SP. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. Expert Opin Pharmacother. 2008 Apr; 9(5):669-76.
Score: 0.067
-
Fox KM, Gandhi SK, Ohsfeldt RL, Davidson MH. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. Am J Manag Care. 2007 Dec; 13 Suppl 10:S270-5.
Score: 0.066
-
Harley CR, Gandhi SK, Anoka N, Bullano MF, McKenney JM. Understanding practice patterns and low-density lipoprotein cholesterol goal attainment implications of switching patients from simvastatin in a health plan setting. Am J Manag Care. 2007 Dec; 13 Suppl 10:S276-81.
Score: 0.066
-
Fox KM, Gandhi SK, Ohsfeldt RL, Blasetto JW, Davidson MH. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database. Clin Ther. 2007 Nov; 29(11):2385-94.
Score: 0.065
-
Fox KM, Gandhi SK, Ohsfeldt RL, Blasetto JW, Bays HE. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States. Curr Med Res Opin. 2007 Sep; 23(9):2125-33.
Score: 0.065
-
Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Am J Geriatr Pharmacother. 2007 Sep; 5(3):185-94.
Score: 0.065
-
Insull W, Ghali JK, Hassman DR, Y As JW, Gandhi SK, Miller E. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Mayo Clin Proc. 2007 May; 82(5):543-50.
Score: 0.063
-
Bullano MF, Kamat S, Wertz DA, Borok GM, Gandhi SK, McDonough KL, Willey VJ. Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting. Am J Health Syst Pharm. 2007 Feb 01; 64(3):276-84.
Score: 0.062
-
Ohsfeldt RL, Gandhi SK, Fox KM, Stacy TA, McKenney JM. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice. Am J Manag Care. 2006 Nov; 12(15 Suppl):S412-23.
Score: 0.061
-
Bullano MF, Wertz DA, Yang GW, Kamat S, Borok GM, Gandhi S, McDonough KL, Willey VJ. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy. 2006 Apr; 26(4):469-78.
Score: 0.059